Search

The present study was aimed to compare the efficacy of metformin 500mg + glimepiride 1mg combination with metformin 500mg+ glimepiride 1mg+ voglibose 0.2mg combination in type 2 diabetes mellitus patients. The primary objective of the study is to compare the efficacy of double drug (metformin & glimepiride) versus triple drug therapy (metformin, glimepiride and voglibose) in type 2 diabetes mellitus subjects and secondary objective is to quantify their effect on glycated haemoglobin (HbA1c) levels in diabetic patient. A total of 100 type-2 diabetic patients were included in the study after obtaining the patient's consent and institutional ethics approval. The study was designed as prospective, nonrandomized, two-arm trial. One hundred type 2 diabetic patients after satisfying the inclusion criteria were included in the study and divided in two groups of 50 each as Group A and Group B. Group A patients received metformin 500mg + glimepiride 1mg, and Group B patients received metformin 500mg + glimepiride 1mg + voglibose 0.2mg. The patient blood samples were analysed for HBA1c, blood sugar levels, serum urea and creatinine during the trial initiation and other follow-ups in 3 months (day0, day15, day30, day45, day60, day75, day90). The obtained data was analysed using chi-square test for non-parametric data and student t-test for parametric data. A significant change in mean HbA1c levels (p value-0.0001) were observed in Group A and Group B patients between the baseline values (7.3±1.4 & 9.7±1.2) and after 3 months treatment values (6.9±1.4 & 7.8±1.1). While comparing the mean HbA1c levels between Group A and Group B after three months of treatment, it was >7.5% in group B patients. No significant effect was seen on serum blood urea of group A and B patients. Triple drug intensification of metformin 500mg with glimepiride 1mg and voglibose 0.2mg showed significant decrease in HbA1c levels during three months of treatment. Further observational studies may be required to provide prolonged treatment data of this combination. [ABSTRACT FROM AUTHOR]